An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB) by Rosenfeld, Margaret et al.
Journal of Cystic Fibrosis xxx (2019) xxx
JCF-01793; No of Pages 6
Contents lists available at ScienceDirect
Journal of Cystic Fibrosis
j ourna l homepage: www.e lsev ie r .com/ locate / j c fOriginal Article
An open-label extension study of ivacaftor in children with CF and
a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB)☆
Margaret Rosenfeld a, Steve Cunningham b, William T. Harris c, Allen Lapey d, Warren E. Regelmann e,
Gregory S. Sawicki f, Kevin W. Southern g, Mark Chilvers h, Mark Higgins i, Simon Tian j, Jon Cooke k,
Jane C. Davies l,⁎,on behalf of the KLIMB study group
a Seattle Children's Hospital, 4800 Sand Point Way NE, Seattle, WA 98105, USA
b University of Edinburgh Centre for Inﬂammation Research and NHS Lothian, Edinburgh, UK
c University of Alabama at Birmingham, 1720 2nd Avenue S, Birmingham, AL 35294, USA
d Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
e University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
f Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA
g University of Liverpool, Liverpool L69 3BX, UK
h British Columbia Children's Hospital, 4480 Oak Street, Vancouver, BC V6H 3N1, Canada
i Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London, W2 6BD, UK
j Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, USA
k Formerly of Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London W2 6BD, UK
l National Heart & Lung Institute, Imperial College London & Royal Brompton Hospital, London SW3 6LR, UKAbbreviations: ALT, alanine transaminase; AST, aspar
immunoreactive trypsinogen; LFT, liver function test; M
limit of normal.
☆ Data from this study were previously presented in pa
Society Winter Meeting 2016; December 7-9, 2019; Lond
⁎ Corresponding author at: Cystic Fibrosis and Chronic
E-mail addresses:margaret.rosenfeld@seattlechildrens
alapey@mgh.harvard.edu (A. Lapey), regel001@umn.edu
mchilvers@cw.bc.ca (M. Chilvers), mark_higgins@vrtx.com
https://doi.org/10.1016/j.jcf.2019.03.009
1569-1993/© 2019 The Authors. Published by Elsevier
creativecommons.org/licenses/by-nc-nd/4.0/).
Please cite this article as: M. Rosenfeld, S. C
a CFTR gating mutation initiating treatmenta b s t r a c ta r t i c l e i n f oArticle history:
Received 29 January 2019
Revised 22 March 2019
Accepted 24 March 2019
Available online xxxxBackground: KIWI (NCT01705145) was a 24-week, single-arm, pharmacokinetics, safety, and efﬁcacy study of
ivacaftor in children aged 2 to 5 years with cystic ﬁbrosis (CF) and a CFTR gating mutation. Here, we report the
results of KLIMB (NCT01946412), an 84-week, open-label extension of KIWI.
Methods: Children received age- and weight-based ivacaftor dosages for 84 weeks. The primary outcome was
safety. Other outcomes included sweat chloride, growth parameters, and measures of pancreatic function.
Results: All 33 children who completed KIWI enrolled in KLIMB; 28 completed 84 weeks of treatment. Most
adverse events were consistent with those reported during KIWI. Ten (30%) children had transaminase eleva-
tions N3 × upper limit of normal (ULN), leading to 1 discontinuation in a child with alanine aminotransferase
N8 × ULN. Improvements in sweat chloride, weight, and body mass index z scores and fecal elastase-1 observed
during KIWI were maintained during KLIMB; there was no further improvement in these parameters.
Conclusions: Ivacaftor was generallywell tolerated for up to 108weeks in children aged 2 to 5 yearswith CF and a
gatingmutation,with safety consistentwith the KIWI study. Improvements in sweat chloride and growth param-
eters during the initial 24 weeks of treatment were maintained for up to an additional 84 weeks of treatment.
Prevalence of raised transaminases remained stable and did not increase with duration of exposure during the
open-label extension.
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Table 1
Adverse events.
Adverse events (AE), n (%) Overall
(N= 33)
Children with ≥1 adverse event 33 (100)
Treatment-emergent adverse events in ≥ 10% of children
Cough 24 (72.7)
Pyrexia 13 (39.4)
Vomiting 13 (39.4)
Pulmonary exacerbation 10 (30.3)
Nasal congestion 7 (21.2)
Increased ALT 7 (21.2)
Increased AST 6 (18.2)
Otitis media 6 (18.2)
Rhinorrhea 6 (18.2)
Abdominal pain 5 (15.2)
Sinusitis 5 (15.2)
Viral upper respiratory tract infection 5 (15.2)
Viral gastroenteritis 4 (12.1)
Streptococcal pharyngitis 4 (12.1)
Rash 4 (12.1)
Serious adverse events (SAEs)
Pulmonary exacerbationa 6 (18.2) Patient # 1, 2, 5, 6, 7, 9
ALT N8 × ULNb 2 (6.1) Patient # 10, 11
AST N5 × ULNb 2 (6.1) Patient # 10, 11
Pyrexiaa 2 (6.1) Patient # 3, 7
Enterovirus infectiona 1 (3.0) Patient # 4
Respiratory syncytial virus infectiona 1 (3.0) Patient # 1
Staphylococcal infectiona 1 (3.0) Patient # 2
Adenovirus test positivea 1 (3.0) Patient # 3
Dehydrationa 1 (3.0) Patient # 3
Anoxic seizurea 1 (3.0) Patient # 8
ALT, alanine transaminase; AST, aspartate transaminase; ULN, upper limit of normal.
a Resulting hospitalization.
b These were the same 2 children. An episode of transaminase N8 × ULN was observed
in a total of 5 children (see Table 2); in only 2 cases did the investigator report the event as
an SAE.
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The pathophysiologic effects of cystic ﬁbrosis (CF), including poor
nutritional status and structural lung damage, typically begin in the
ﬁrst years of life [1]. Early intervention is known to be clinically beneﬁ-
cial [2,3], and thus treatment with cystic ﬁbrosis transmembrane con-
ductance regulator (CFTR) modulators early in life could potentially
improve long-term outcomes. To date, no studies have been conducted
on prolonged use of CFTRmodulators in childrenwith CFwho are youn-
ger than 6 years of age.
Ivacaftor, a CFTR potentiator that enhances chloride transport by in-
creasing the channel-open probability of CFTR at the cell surface [4,5],
has been shown to be safe and efﬁcacious in patients aged 6 years and
older with CF and speciﬁc CFTR mutations [6–9]. The 24-week, open-
label, 2-part, phase 3 KIWI study demonstrated that the pharmacokinet-
ics, safety, and efﬁcacy of ivacaftor in children aged 2 to 5 years with CF
and a CFTR gating mutation are generally similar to those seen in older
patients [10]. Data from KIWI led to the approval of ivacaftor in the
United States, European Union, Canada, and Australia for treatment of
patients aged 2 years and older with CF and a CFTR gating/ivacaftor-
responsive mutation.
Here, we report results from KLIMB, an 84-week extension study of
ivacaftor in children aged 2 to 5 years with CF and a CFTR gating muta-
tionwho completed the 24-week KIWI study. Theprimary outcomewas
long-term safety. Other outcomes included changes in sweat chloride,
growth parameters, and measures of pancreatic function.
2. Methods and materials
2.1. Study design and participants
KLIMB was an open-label extension study (ClinicalTrials.gov, num-
ber NCT01946412) in children who completed the 24-week, single-
arm, open-label, phase 3 KIWI (part B) study of ivacaftor treatment
[10]. Children eligible for KIWI were aged 2 to 5 years (median,
3.0 years), weighed 8 kg or more, and had a conﬁrmed diagnosis of CF
[11] and a CFTR gating mutation (G551D, G178R, S549N, S549R, G551S,
G970R, G1244E, S1251N, S1255P, G1349D) on at least 1 allele [10]. After
completion of the study's design, the G970Rmutation was discovered
to be a class I splice mutation [12]; none of the children in this study
had this mutation. There was no interruption of ivacaftor treatment be-
tween KIWI and KLIMB. The primary outcome of KLIMB was long-term
safety. Other outcomes included change from KIWI and KLIMB study
baseline measurements in sweat chloride (assessed at clinic visits at
day 1 and weeks 24, 48, 72, and 84) and weight, height, and body
mass index (BMI; assessed at day 1 and weeks 12, 24, 36, 48, 60, 72,
and 84). Exploratory endpoints included change from KIWI and KLIMB
study baseline measurements in fecal elastase-1 (a measure of pancre-
atic exocrine function [13]), and percent predicted forced expiratory
volume in 1 s (ppFEV1), all assessed at day 1 and weeks 12, 24, 36, 48,
60, 72, and 84. Immunoreactive trypsinogen (IRT; a serum-based
marker of pancreatic insult) was assessed at day 1 and weeks 24, 48,
60, 72, and 84 [14]. Neither the site staff nor enrolled children received
study-speciﬁc training in preschool lung function testing, nor were
certiﬁcation or over-reading conducted for spirometric assessments.
Because acceptable spirometric datawere only obtained in a small num-
ber of children in KIWI, these results are not presented.
This study was conducted at 15 sites in the United States, United
Kingdom, and Canada fromDecember 2013 toDecember 2015. Children
received weight-based ivacaftor as granules (Vertex Pharmaceuticals
Incorporated, Boston, MA) every 12 h (q12h) at a dose of 50 mg q12h
(weight b 14 kg) and 75 mg q12h (weight ≥ 14 kg). Children who
turned 6 years of age during KLIMB received ivacaftor 150 mg q12h as
tablets (Vertex Pharmaceuticals Incorporated, Boston, MA). Dose was
adjusted as necessary based onweight at each study visit. Safety assess-
ments consisted of adverse events primarily deﬁned using CommonPlease cite this article as: M. Rosenfeld, S. Cunningham, W.T. Harris, et al
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laboratory values, vital signs, 12-lead electrocardiogram readings, and
physical and ophthalmological examinations. Standardized eye exami-
nations were conducted by a licensed ophthalmologist at baseline and
at speciﬁed intervals after dosing. Serious adverse events were deﬁned
per the International Conference on Harmonisation guidelines [16].
An independent ethics committee or institutional review board for
each site approved the study protocol, and an independent data moni-
toring committee monitored study safety data. Written informed con-
sent was obtained from each child's parent or legal guardian.
2.2. Statistical analyses
Safety and efﬁcacy were assessed among all children who received
at least 1 dose of ivacaftor in KLIMB. Amixed-effects model for repeated
measures (MMRM)was used to analyze the absolute change from base-
line in sweat chloride; height, weight, and BMI z scores; and fecal
elastase-1 at each study visit. For IRT, as it was not normally distributed,
the Wilcoxon Signed Rank Test was used. There was no adjustment for
multiple comparisons in the analyses of absolute change from baseline
in study endpoints due to the small sample size. All P values are nomi-
nal. Additional analyses performed using descriptive statistics and 95%
CI for group comparisons are provided. Analyses were performed
using SAS®, version 9.2 (Cary, NC).
3. Results
3.1. Study population
Thirty-four childrenwere enrolled in KIWIpart B, and 33 (97%) com-
pleted the 24 weeks of treatment (Supplementary Fig. 1). All 33 who
completed KIWI enrolled in KLIMB, with 28 (84.8%) completing the., An open-label extension study of ivacaftor in children with CF and
urnal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2019.03.009
Table 2
Summary of liver function test elevations during the 84-week KLIMB study.
Maximum on-treatment ALT or AST (U/L), n (%)a N = 33
N3 to ≤5 × ULN 1 (3.0)
N5 to ≤8 × ULN 4 (12.1)
N8 × ULN 5 (15.2)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit
of normal.
a 7 of the 10 total events were reported as AEs; 2 of the 5 events with ALT or AST N8 ×
ULN were reported as SAEs.
3M. Rosenfeld et al. / Journal of Cystic Fibrosis xxx (2019) xxx84-week open-label treatment period. Of the 5 children who
discontinued study drug before week 84, 2 switched to commercial
ivacaftor, 1 had an adverse event (elevated alanine aminotransferase
[ALT] N8 × upper limit of normal [ULN] and aspartate aminotransferase
[AST] N3 × ULN), 1 had difﬁculty swallowing the ivacaftor 150-mg tab-
let, and 1 withdrew because of inability to tolerate further blood tests.3.2. Primary outcome: safety
Adverse events are summarized in Table 1. All children reported at
least 1 adverse event during the 84 weeks. The most common adverse
events occurring in ≥30% of children were cough (72.7%), pyrexia
(39.4%), vomiting (39.4%), and pulmonary exacerbation (30.3%), events
that commonly occur in the pediatric CF population. Twenty-one seri-
ous adverse events occurred in 11 children. Serious adverse events con-
sidered related to ivacaftor were elevated ALT and AST levels that
occurred in 2 children. One child had elevated ALT levels N8 × ULN
and elevated AST levels N5 × ULN on the same day. The second had ele-
vated ALT/AST levels N8 × ULN on the same day.
Elevated ALT and/or AST levels N3 × ULN were documented in 10
children (30%) during 84 weeks in KLIMB (Table 2). 4 of these 10 chil-
dren also had transaminase elevations during KIWI, and a history of
liver function test (LFT) elevations before enrollment in KIWI. In
KLIMB, LFT elevations were reported as adverse events in 7 of the 10
children. Per protocol, treatment was interrupted in all 5 children who
reported ALT and/or AST elevations N8 × ULN. Ivacaftor dosingwas suc-
cessfully resumed in 4 of the 5 children. One child permanently
discontinued ivacaftor because of LFT elevations after ivacaftor was
reinitiated.P
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during KLIMB. There was no evidence of increased prevalence of ele-
vated transaminases with prolonged exposure to ivacaftor.
No abnormalities were detected on serial electrocardiograms. No
meaningful changes in visual acuity from baseline occurred throughout
the study. One child with a history of astigmatism developed a lens
opacity at week 84 that was considered not visually signiﬁcant and pos-
sibly related to ivacaftor. Drug withdrawal was not recommended.
3.3. Secondary outcomes
3.3.1. Sweat chloride
Ivacaftor treatment during KIWI had led to a signiﬁcant reduction in
sweat chloride that was maintained over 24 weeks of treatment [10].
Continued treatment of these children with ivacaftor in KLIMB main-
tained this reduction in sweat chloride until the end of the study at
week 84 (Fig. 2 and Table 3).
3.3.2. Nutrition
Improvements in weight z score (+0.2 [SD, 0.3]; P b .0001) and BMI
z score (+0.4 [SD, 0.4]; P b .001) were observed during the initial 24-
week KIWI study [10]. During the 84-weekKLIMB extension, theweight
z score from KIWI baseline was unchanged but the BMI z score contin-
ued to be signiﬁcantly better than at KIWI baseline (0.27 [95% CI: 0.04,
0.50]; Table 3).
3.4. Exploratory outcomes
3.4.1. Pancreatic exocrine function
In the KIWI study, mean fecal elastase-1 increased by 99.8 μg/g from
baseline (SD, 138.4; P b .001). Additionally, 23% (P= .0504) had a fecal
elastase-1 that improved to N200 μg/g, the cutoff value for pancreatic
exocrine insufﬁciency. Improvements in fecal elastase-1 levels observed
during KIWI were maintained during KLIMB (Fig. 2). At week 84, the
mean (95% CI) absolute increase in fecal elastase-1 was 128.8 (45.7,
211.9) μg/g from KIWI baseline. During the 84-week open-label exten-
sion, fecal elastase-1 continued to increase, but the change from
KLIMB baseline was not statistically signiﬁcant (56.8 μg/g; 95% CI:
−22.2, 135.8; Table 3). Seventeen children had paired fecal elastase-1
data at KIWI baseline and week 84 of KLIMB. At the start of the KIWI
study, 1 of 17 (6%) children had fecal elastase-1 levels ≥200 μg/g.isit
t
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4 M. Rosenfeld et al. / Journal of Cystic Fibrosis xxx (2019) xxxBy week 84 of KLIMB, 6 of 17 (35%) children had fecal elastase-1 ≥ 200
μg/g.
In KIWI, IRT levels decreased from baseline to week 24 by a mean of
20.7 ng/mL (SD, 24), suggesting reduced pancreatic inﬂammation/
stress from KIWI study entry [10]. This decrease was maintained in
KLIMB: at week 84, the mean (SD) absolute decrease from KIWI base-
line was −15.9 (25.2) ng/mL. The median (range) absolute decreaseKIWIa K
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change during the KLIMB extension (1.0 ng/mL;−16.4, 35.6).
4. Discussion
The results of this open-label extension study suggest that ivacaftor
is generally well tolerated in children aged 2 to 5 years with CF and a
gating mutation for up to 108 weeks. The safety proﬁle was consistentLIMB
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Table 3
Absolute change in secondary and tertiary endpoints at extension week 84.
Endpoints Mean absolute change at extension week 84 (95% CI) P value for mean absolute change from KIWI baselinea
Secondary endpoints From KIWI baseline From KLIMB baseline
Sweat chloride, mmol/L −54.7 (−65.4,−43.9) −8.5 (−18.9, 1.8) b.0001
Tertiary endpoints
BMI z score 0.27 (0.04, 0.50) −0.08 (−0.31, 0.15) .0229
Weight z score 0.20 (−0.05, 0.44) 0.00 (−0.20, 0.20) .1119
Height z score 0.12 (−0.06, 0.29) 0.14 (0.00, 0.29) .1800
Fecal elastase-1, μg/g 128.8 (45.7, 211.9) 56.8 (−22.2, 135.8) .0050
Median absolute change (min,max) at extension week 84
IRT, ng/mL −8.1 (−71.1, 21.9) 1.0 (−16.4, 35.6) .0103b
BMI, body mass index; IRT, immunoreactive trypsinogen.
a All P values are nominal.
b From a Wilcoxon Signed Rank Test.
5M. Rosenfeld et al. / Journal of Cystic Fibrosis xxx (2019) xxxwith previous clinical trials of ivacaftor in children and adults. There
were no clinical safety concerns identiﬁed in assessments of hematol-
ogy laboratory parameters, vital signs, or electrocardiograms in this
small sample.
While there are limited data on the prevalence of LFT elevations in
children with CF, studies indicate a natural propensity for transaminase
elevations in children with CF in the ﬁrst 2 to 3 years of life [17,18]. Our
ﬁndings on transaminase elevations seem to be consistent with the pub-
lished data. Thirty percent of children aged 2 to 5 years in KLIMB had
transaminase elevations N3 × ULN on at least 1 occasion across
84 weeks. Transaminase elevations were generally asymptomatic, did
not require permanent treatment discontinuation except in 1 child, and
occurredmore often in childrenwith a history of transaminase elevations
prior to ivacaftor exposure and in KIWI. The lack of a placebo arm in this
study makes interpretation of our results difﬁcult, with uncertainty as to
whether the prevalence of elevated transaminases reﬂects an effect of
ivacaftor, ascertainment bias due to increasedmonitoring during a clinical
trial, or the natural history of LFT elevations in this age group. This long-
term extension study is important in demonstrating that the prevalence
of LFT elevations did not appear to increase with the length of exposure
to ivacaftor. However, it is recommended that LFTs be assessed before ini-
tiation of ivacaftor and monitored during treatment, particularly in chil-
dren with a history of elevated transaminases.
It is difﬁcult to interpret the potential risk of the non-visually signif-
icant lens opacity seen in 1 patient at week 84 in association with astig-
matism. Baseline assessment for lens opacities and periodic monitoring
while on therapy is recommended.
The improvements observed in sweat chloride concentrations dur-
ing the 24-week KIWI study were maintained during this 84-week ex-
tension trial, demonstrating maintenance of improved CFTR function.
Similarly, improvements in BMI z scores observed in KIWI were gener-
ally maintained in KLIMB, although without further improvement.
The changes in the exploratory endpoints of fecal elastase-1 and
serum IRT observed during KIWI were maintained during KLIMB, sug-
gesting that early, effective CFTR modulation has the potential to delay
deterioration in pancreatic function. Further support is lent to this
hypothesis by the improvements in markers of pancreatic exocrine
function (fecal elastase-1) and pancreatic insult (IRT, amylase, and
lipase) reported recently in children 12 to b24 months treated with
ivacaftor [19]. The mechanism by which ivacaftor might improve
exocrine pancreatic function is unclear. In a recent study employing
mouse models of Sjogren's syndrome and autoimmune pancreatitis,
both of which involve decreased expression and mislocalization of
CFTR in the pancreatic ducts, treatment with ivacaftor and a CFTR cor-
rector rescued CFTR expression and localization, resulting in decreased
acinar inﬂammation, ﬁbrosis, and tissue damage [20]. These results
(albeit not from a CF model) suggest that the effect of ivacaftor on the
pancreas in infants and toddlers with CF may bemediated through res-
toration of ductal function, in turn improving acinar cell function andPlease cite this article as: M. Rosenfeld, S. Cunningham, W.T. Harris, et al
a CFTR gating mutation initiating treatment at age 2–5years (KLIMB)..., Jouallowing some normalization of pancreatic secretions (enzymes,
bicarbonate, ﬂuid). In older children and adults, in whom ivacaftor
does not improve fecal elastase, the improved nutritional status associ-
atedwith ivacaftor appears to be the result of normalization of intestinal
pH and CFTR-mediated bicarbonate secretion [21] as well as decreased
intestinal inﬂammation, resulting in improved absorption of fat [22].
The current study had several limitations. The age of the population
and relative rarity of the CFTR gating mutations led to the decision to
perform the original KIWI study as an open-label rather than a
placebo-controlled trial. Because KLIMB was designed as a single-arm
extension of this safety and pharmacokinetic trial, there was no placebo
group. The lack of a control group limits our interpretation of both safety
and therapeutic beneﬁt. In addition, most participants had at least 1
G551D mutation, limiting our ability to assess the effects of ivacaftor
treatment in persons with rarer gating mutations. The small sample
size also limited our ability to detect rare adverse events. Finally, be-
cause of the challenge of obtaining accurate spirometry data from chil-
dren aged 2 to 5 years [23], very little acceptable spirometry data
were collected, precluding our ability to analyze those data. Alternative
lung functionmeasures such as the lung clearance index frommultiple-
breath washout may also be considered in the future [24].
5. Conclusions
This is the ﬁrst study reporting long-term safety and efﬁcacy of
ivacaftor in children aged 2 to 5 years with a CFTR gating mutation.
Ivacaftor was generally safe and well tolerated for up to 108 weeks. In-
creases in transaminases did not becomemore frequentwith prolonged
exposure to the drug. The reduction in sweat chloride concentration,
growth beneﬁts, and improvements in markers of pancreatic exocrine
function observed during 24 weeks in KIWI were maintained for an ad-
ditional 84 weeks in KLIMB.
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